The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Inhalable Biologics Market By 2030 Starting From Its 2026 Size?
The inhalable biologics market size has seen rapid expansion in recent years. It is anticipated to grow from $3.22 billion in 2025 to $3.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.7%. The growth observed in the historic period can be attributed to factors such as the increasing prevalence of respiratory diseases, the limitations associated with injectable biologics, ongoing advancements in inhalation device technology, an expanding biologics pipeline, and the rise in hospital-based respiratory care.
The inhalable biologics market size is anticipated to undergo significant expansion over the next few years. It is predicted to reach $6.67 billion in 2030, with a compound annual growth rate (CAGR) of 15.6%. This projected growth can be attributed to several factors, including the increase in chronic respiratory disorders, the broadened application of inhalable biologics beyond respiratory conditions, a rising patient preference for non-invasive treatments, continuous advancements in formulation stability, and increased investments in pulmonary drug delivery research. Dominant trends during this forecast period are expected to include the expansion of pulmonary delivery for systemic biologics, the growing utilization of dry powder inhalers for biologics, an intensified focus on targeted lung drug delivery, the increasing development of inhalable monoclonal antibodies, and the adoption of patient-friendly non-invasive biologic therapies.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24253&type=smp
What Primary Drivers Are Shaping The Development Of The Inhalable Biologics Market?
The expanding prevalence of respiratory ailments is projected to boost the growth of the inhalable biologics market. These conditions encompass illnesses and disorders impacting the lungs, airways, nasal passages, and other components of the respiratory system. The rise in respiratory conditions is linked to heightened air pollution, which exacerbates issues such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer by exposing individuals to harmful particulate matter and other pollutants. Inhalable biologics offer advantages for respiratory conditions through their direct delivery of targeted therapy to the lungs, which helps in reducing inflammation and enhancing lung function with fewer systemic side effects. As an illustration, in June 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, indicated that in 2023, COPD constituted 3.6% of the overall disease burden and 50% of the respiratory disease burden. Consequently, the growing incidence of respiratory conditions is a major factor contributing to the expansion of the inhalable biologics market.
Which Segment Categories Define The Inhalable Biologics Market?
The inhalable biologics market covered in this report is segmented –
1) By Type: Peptides And Proteins, Vaccines, Monoclonal Antibodies, RNAi-Based Therapeutics, Other Types
2) By Dosage Form: Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers, Other Dosage Forms
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Respiratory Diseases, Diabetes, Cancer, Other Applications
Subsegments:
1) By Peptides And Proteins: Insulin, Growth Hormones, Enzyme Replacement Therapies, Other Peptides And Proteins
2) By Vaccines: Influenza Vaccines, Other Respiratory Vaccines
3) By Monoclonal Antibodies: Respiratory Monoclonal Antibodies, Immunomodulatory Monoclonal Antibodies, Other Monoclonal Antibodies
4) By RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases, Other RNAi-Based Therapeutics
5) By Other Types: Gene Therapies, Small Molecule Inhalable Drugs, Other Innovative Inhalable Biologics
What Major Market Trends Are Driving Changes In The Inhalable Biologics Market?
Leading companies in the inhalable biologics market are prioritizing the creation of innovative solutions, such as inhaled insulin, to boost patient compliance and achieve rapid glycemic control. Inhaled insulin represents a form of insulin that reaches the bloodstream through the lungs via inhalation, rather than through injections or insulin pumps. This technique involves breathing in a powdered or aerosolized version of insulin, which the lungs absorb and quickly introduces into the bloodstream to assist in regulating blood sugar levels. For instance, in February 2025, Cipla Limited, an India-based pharmaceutical company, secured regulatory approval from the Central Drugs Standard Control Organization for Afrezza, acknowledged as the world’s fastest inhaled insulin. This offers a revolutionary, needle-free option for adults with type 1 and type 2 diabetes. This ultra-rapid-acting insulin becomes effective within 12 to 15 minutes of inhalation, closely mimicking the body’s natural insulin response to meals and improving overall blood sugar management. The availability of inhaled insulin provides a more comfortable choice over multiple daily injections, especially benefiting patients experiencing injection anxiety and thereby improving adherence to their insulin therapy.
Who Are The Top Companies Competing In The Inhalable Biologics Market?
Major companies operating in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann-La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation
Read the full inhalable biologics market report here:
https://www.thebusinessresearchcompany.com/report/inhalable-biologics-global-market-report
How Does The Inhalable Biologics Market Perform Across Major Global Regions?
North America was the largest region in the inhalable biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalable biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Inhalable Biologics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24253&type=smp
Browse Through More Reports Similar to the Global Inhalable Biologics Market 2026, By The Business Research Company
Inhalable Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/inhalable-drugs-global-market-report
Inhalation Cdmo Market Report 2026
https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report
Inhalation Anesthesia Market Report 2026
https://www.thebusinessresearchcompany.com/report/inhalation-anesthesia-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model